SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-007585
Filing Date
2022-05-05
Accepted
2022-05-05 09:01:23
Documents
12
Period of Report
2022-05-05
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K tptx-20220505.htm   iXBRL 8-K 54800
  Complete submission text file 0000950170-22-007585.txt   170316

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tptx-20220505_pre.xml EX-101.PRE 9557
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tptx-20220505_lab.xml EX-101.LAB 12890
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tptx-20220505.xsd EX-101.SCH 2513
6 EXTRACTED XBRL INSTANCE DOCUMENT tptx-20220505_htm.xml XML 4553
Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Filer) CIK: 0001595893 (see all company filings)

IRS No.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38871 | Film No.: 22894324
SIC: 2834 Pharmaceutical Preparations